Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus : Are We Respecting Their Contraindications?
Ruiz Tamayo, Irene (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Franch-Nadal, Josep (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Mata Cases, Manel (Institut Català de la Salut)
Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Cos Claramunt, Francesc Xavier (Institut Català de la Salut)
Rodríguez Poncelas, Antonio (Institut Català de la Salut)
Barrot de la Puente, Joan (Institut Català de la Salut)
Coll-de-Tuero, Gabriel (Institut Català de la Salut)
Mundet-Tudurí, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2016
Abstract:	Aim. To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder cancer. Methods. Cross-sectional, descriptive, multicenter study. Electronic medical records were retrieved from all T2DM subjects who attended primary care centers pertaining to the Catalan Health Institute in Catalonia in 2013 and were pharmacologically treated with any NIAD alone or in combination. Results. Records were retrieved from a total of 255,499 pharmacologically treated patients. 78% of patients with some degree of renal impairment (glomerular filtration rate (GFR) < 60 mL/min) were treated with metformin and 31. 2% with sulfonylureas. Even in the event of severe renal failure (GFR < 30 mL/min), 35. 3% and 22. 5% of patients were on metformin or sulfonylureas, respectively. Moreover, metformin was prescribed to more than 60% of patients with moderate or severe heart failure. Conclusion. Some NIADs, and in particular metformin, were frequently used in patients at high risk of complications when they were contraindicated. There is a need to increase awareness of potential inappropriate prescribing and to monitor the quality of prescribing patterns in order to help physicians and policymakers to yield better clinical outcomes in T2DM.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Journal of Diabetes Research, Vol. 2016 (January 2016) , art. 7502489, ISSN 2314-6753

DOI: 10.1155/2016/7502489
PMID: 26881258

9 p, 569.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles